SCHEMBL5473778

SCHEMBL5473778

COc1cc2ncnc(Nc3ccc(C)cc3)c2cc1OC

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 15/20 0.80
KDR P35968 9/20 0.80
LCK P06239 5/20 0.80
RET P07949 4/20 0.78
RIPK2 O43353 2/20 0.78
FLT1 P17948 1/20 0.78
GAK O14976 1/20 0.78
STK10 O94804 1/20 0.78
FLT3 P36888 1/20 0.78
JAK3 P52333 1/20 0.78
AAK1 Q2M2I8 1/20 0.78
Q6ZSR9 Q6ZSR9 1/20 0.78
SLK Q9H2G2 1/20 0.78
IRAK4 Q9NWZ3 1/20 0.78
RPS6KA6 Q9UK32 1/20 0.78
ALK Q9UM73 1/20 0.78
CLK1 P49759 1/20 0.77
ABCG2 Q9UNQ0 1/20 0.77
KIF5B P33176 2/20 0.70
EPHB2 P29323 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5473795 0.99 EGFR (0.80) EGFRKDRLCKRETRIPK2
SCHEMBL14159636 0.91 KDR (0.73) EGFRKDRLCKRETRIPK2
SCHEMBL31067650 0.90 KDR (0.83) EGFRKDR
SCHEMBL5467825 0.89 EGFR (1.00) EGFRKDRLCKRETRIPK2
SCHEMBL3533221 0.89 EGFR (0.80) EGFRKDRLCKRETRIPK2
SCHEMBL5472599 0.89 EGFR (1.00) EGFRKDRLCKRETRIPK2
SCHEMBL5477771 0.87 KDR (1.00) EGFRKDRLCKRETRIPK2
SCHEMBL1387182 0.87 EGFR (0.94) EGFRKDRLCKRETRIPK2
Whi-P131 SCHEMBL29295 0.87 EGFR (1.00) EGFRKDRLCKRETRIPK2
SCHEMBL5473780 0.87 EGFR (0.78) EGFRKDRLCKRETRIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118852128-A Quinazoline derivative containing 2-indolone as well as preparation method and application thereof 成都安博力善生物科技有限公司 2024-10-29 CN disclosed
US-11806555-B2 Methods for treating hair loss disorders THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-11-07 US disclosed
US-9895301-B2 Methods for treating hair loss disorders THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2018-02-20 US disclosed
US-9763866-B2 Methods for treating hair loss disorders THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2017-09-19 US disclosed
US-9737469-B2 Methods for treating hair loss disorders THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2017-08-22 US disclosed
US-9730877-B2 Methods for treating hair loss disorders THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2017-08-15 US disclosed
US-20160256374-A1 METHODS FOR TREATING HAIR LOSS DISORDERS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2016-09-08 US disclosed
US-20160256461-A1 METHODS FOR TREATING HAIR LOSS DISORDERS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2016-09-08 US disclosed
US-20160058764-A1 METHODS FOR TREATING HAIR LOSS DISORDERS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2016-03-03 US disclosed
US-20160058765-A1 METHODS FOR TREATING HAIR LOSS DISORDERS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2016-03-03 US disclosed
US-9198911-B2 Methods for treating hair loss disorders THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2015-12-01 US disclosed
US-20140065153-A1 Methods for Treating Hair Loss Disorders THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2014-03-06 US disclosed
US-8513267-B2 4-anilinoquinazoline derivatives with adenosine-kinase inhibitor properties UNIVERSIDADE ESTADUAL DE CAMPINAS-UNICAMP (BR) 2013-08-20 US disclosed
EP-1737832-B1 4-ANILINOQUINAZOLINE DERIVATIVES WITH ADENOSINE-KINASE INHIBITORY PROPERTIES UNICAMP (BR) 2011-12-14 EP disclosed
US-7709479-B1 Quinazoline derivatives and their use as pharmaceuticals ASTRAZENECA (SE) 2010-05-04 US disclosed
US-20070060600-A1 4-Anilinequinazolines with adenosine-kiase inhibitor properties UNIVERSIDADE ESTADUAL DE CAMPINAS-UNICAMP (BR) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11806555-B2 Methods for treating hair loss disorders PRKACB, PRKACA, PRKACG EGFR 625/4885KDR 3903/4885LCK 112/4885
US-20160058765-A1 METHODS FOR TREATING HAIR LOSS DISORDERS PRKACB, PRKACA, PRKACG EGFR 625/4885KDR 3903/4885LCK 112/4885
US-20160256461-A1 METHODS FOR TREATING HAIR LOSS DISORDERS PRKACB, PRKACA, PRKACG EGFR 625/4885KDR 3903/4885LCK 112/4885
US-20160256374-A1 METHODS FOR TREATING HAIR LOSS DISORDERS PRKACB, PRKACA, PRKACG EGFR 625/4885KDR 3903/4885LCK 112/4885
US-20160058764-A1 METHODS FOR TREATING HAIR LOSS DISORDERS PRKACB, PRKACA, PRKACG EGFR 625/4885KDR 3903/4885LCK 112/4885
US-20070060600-A1 4-Anilinequinazolines with adenosine-kiase inhibitor properties ADK, AK1, ADORA3 EGFR 3142/4885KDR 1289/4885LCK 860/4885
US-20140065153-A1 Methods for Treating Hair Loss Disorders JAK3, JAK2, JAK1 EGFR 549/4885KDR 4166/4885LCK 171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.